Crenolanib (CP-868,596)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:34, 7 November 2014 by Jwarner (talk | contribs)
Jump to navigation Jump to search

In clinical trials

Preliminary Data

  1. Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Crenolanib_(CP-868,596)&oldid=5474"